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Toll-like receptors (TLR) are key regulators of innate immune and inflammatory responses
and their activation is linked to impaired glucose metabolism during metabolic disease.
Determination of whetherTLR4 signaling can be activated in the heart by insulin may shed
light on the pathogenesis of diabetic cardiomyopathy, a process that is often complicated
by obesity and insulin resistance. The aim of the current study was to determine if supra-
physiological insulin concentrations alter the expression ofTLR4, markers ofTLR4 signaling
and glucose transporters (GLUTs) in the heart. Firstly, the effect of insulin on TLR4 protein
expression was investigated in vitro in isolated rat cardiac myocytes. Secondly, protein
expression ofTLR4, the pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis
factor-alpha (TNF-α) suppressor of cytokine signaling 3 (SOCS3) and GLUTs (1, 4, 8, 12) were
examined in the equine ventricular myocardium following a prolonged, euglycemic, hyper-
insulinemic clamp. Down-regulation of TLR4 protein content in rat cardiac myocytes was
observed after incubation with a supraphysiologic concentration of insulin as well as in the
equine myocardium after prolonged insulin infusion. Further, cardiac TLR4 expression was
negatively correlated with serum insulin concentration. Markers of cardiac TLR4 signaling
and GLUT expression were not affected by hyperinsulinemia and concomitantTLR4 down-
regulation. Since TLRs are major determinants of the inflammatory response, our findings
suggest that insulin infusion exerts an anti-inflammatory effect in the hearts of non-obese
individuals. Understanding the regulation of cardiac TLR4 signaling during metabolic dys-
function will facilitate improved management of cardiac sequela to metabolic syndrome
and diabetes.
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INTRODUCTION
Metabolic diseases, which include insulin resistance (IR) and
metabolic syndrome, are at the forefront of public health con-
cern due to the global obesity epidemic (1, 2). Importantly, IR can
persist for many years in human patients before pancreatic decom-
pensation results in the development of diabetes. However, the
early pathophysiological mechanisms underlying the long latency
period preceding overt diabetes are largely undefined (3). Termed
metabolic syndrome, the disease is characterized by hyperinsu-
linemia and occurs in both humans and animals (4). Interestingly,
horses often develop a variant of metabolic syndrome (called
equine metabolic syndrome), which is primarily characterized by
IR that can persist for years. Similar to humans and small ani-
mals, equine metabolic syndrome is also increasingly diagnosed in
current times, with equine obesity and IR burgeoning thanks to
concentrate-rich diets and reduced levels of exercise (4, 5). Con-
sidering that horses with IR exhibit similar features to metabolic
diseases in other species, including humans and small animals,
comparative metabolism studies in both small and large animals
may aid in further elucidating the pathophysiology of metabolic
dysfunction across species. Importantly, the recent development of
a prolonged, euglycemic, hyperinsulinemic clamp in healthy, adult,
disease free horses that are not prone to cardiovascular disease or
diabetes mellitus has resulted in an unprecedented opportunity
to study the effect of prolonged hyperinsulinemia in this unique
large animal model.
The inability of cells to respond appropriately to insulin, which
stimulates glucose uptake into the cell, is the hallmark of IR (6).
Glucose uptake is tightly regulated by facilitated diffusion and
is mediated primarily by a family of membrane proteins called
glucose transporters (GLUTs). Reduced glucose uptake not only
results in hyperglycemia, which feeds back to stimulate further
insulin release by the pancreas thereby creating or exacerbat-
ing hyperinsulinemia, but also leads to cellular and target organ
dysfunction. Sequela to defective glucose metabolism are leading
causes of morbidity and include cardiovascular disease, impaired
wound healing, retinal degeneration, and renal failure (7–9).
Impaired glucose metabolism and chronic inflammation in the
heart leads to diabetic cardiomyopathy, which is a common and
serious consequence of uncontrolled metabolic dysfunction (10).
www.frontiersin.org July 2014 | Volume 5 | Article 120 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
de Laat et al. Hyperinsulinemia and cardiac TLR4
The activation of toll-like receptor (TLR) signaling is essential
for innate immune system regulation and results in up-regulation
of inflammatory pathways and the release of inflammatory
cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-
alpha (TNF-α) (11). However, the role of TLRs in non-immune
cells such as the cardiac myocyte, to which inflammation is harm-
ful, is not well defined. Two TLR isoforms (2 and 4) have been
identified at the myocyte surface and have been implicated in
ischemic cardiac injury and reduced cardiac myocyte survival (12).
Although their potential for playing a pathogenic role in diabetic
cardiomyopathy is not well evaluated, recent studies have sug-
gested that TLR signaling is linked to impaired glucose metabolism
by altering the regulation of glucose transport (11).
Lipopolysaccharide is the classical ligand for TLR4, although
free fatty acids (FFAs) are also thought to be key activators of
TLR signaling during metabolic disease (13). More recently, stud-
ies on TLR4 activation during type 1 diabetes have indicated
that other host-derived molecules are capable of regulating TLR4
function (14–16). Importantly, a recent study showed that short-
term insulin infusions administered to type 1 diabetic patients
decreased TLR expression in mononuclear cells (14). However,
similar regulation of TLR signaling in non-immune cells has
not been investigated. Determining if insulin is able to modu-
late TLR4 signaling in the heart may lead to identification of novel
mechanisms of metabolic inflammatory disease as well as novel
therapeutic targets.
The aims of the current study were to: (1) determine the effect
of hyperinsulinemia using both in vitro and in vivo approaches,
on cardiac TLR4 expression in non-obese animals, and (2) inves-
tigate the impact of altered cardiac TLR4 expression during
hyperinsulinemia on markers of TLR4 signaling (IL-6, TNF-α,
and SOCS3) and cardiac GLUT (1, 4, 8, 12) expression. To this
end, we used an integrative physiological approach, including an
in vitro investigation of small animal myocardial TLR4 responsive-
ness to insulin, and a well-characterized large animal model that
enables examination of non-obese, prolonged hyperinsulinemic
states (17, 18).
MATERIALS AND METHODS
All described experimental protocols were approved by the Animal
Care and Use Committee of Oklahoma State University (VM-
12-3) and the Animal Ethics Committee of the University of
Queensland (SVS/013/08/RIRDC).
CARDIAC MYOCYTE ISOLATION
Healthy Wistar rats (n= 5) were anesthetized with an intraperi-
toneal injection of pentobarbital sodium (1.2 mL). Once profound
anesthesia was achieved, heart extraction preceded immediate can-
nulation of the aorta. Cardiac myocytes were isolated as previously
described (19). Briefly, the heart was perfused in a retrograde man-
ner, using a Langendorff apparatus with Krebs Henseleit (KH)
buffer (pH 7.4, 37°C, pH 7.35, and oxygenated with 95% O2
and 5% CO2), containing (in millimolar): 118 NaCl, 4.7 KCl,
1.2 MgSO4, 1.25 CaCl2, 1.2 KH2PO4, 25 NaHCO3, 11 glucose.
Enzymatic digestion was achieved with collagenase (Worthington,
NJ, USA). A minimum yield of 80% live myocytes (rod-shaped
cells with sharp margins and clear striations), identified with a
light microscope immediately following isolation, was considered
acceptable.
Following isolation, live myocytes were incubated in triplicate
in KH buffer (with 0.125 mM CaCl2) under basal conditions or
treated with insulin and/or glucose as follows. Myocytes were
incubated with no insulin, 100 or 500µ IU/mL (physiological or
supraphysiological concentration, respectively) of insulin in the
presence of physiological (5 mM) or high (25 mM) concentrations
of glucose. Following 60 min incubation, myocytes were washed
prior to cell solubilization [50 mM Tris-HCl, pH 8.0, 150 mM
sodium chloride, 1.0% Igepal CA-630 (NP 40), 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate with a protease
inhibitor cocktail] and protein extraction.
PROLONGED, EUGLYCEMIC, HYPERINSULINEMIC CLAMP
Prolonged marked hyperinsulinemia was induced by the com-
bined infusion of insulin (constant rate, Humulin-R, 6 m IU/kg
BW/min) and glucose (variable rate) for 46± 2.3 h to maintain
a stable blood glucose concentration of 5± 1 mM in a large ani-
mal model, as previously described (18, 20). Standardbred horses
treated with a prolonged, euglycemic, hyperinsulinemic clamp (p-
EHC) were matched (age and weight) with healthy control horses
that were administered a balanced electrolyte solution (n= 4 per
group). Blood samples (10 mL) were collected at the start and
again at the end of the clamp to determine blood glucose and
serum insulin concentrations. Blood glucose was analyzed using
fresh, whole blood with a handheld glucometer (Accu Check-Go,
Roche); insulin concentration was determined on serum (stored
at −80°C) using a radioimmunoassay (Coat-a-count, Siemens
Healthcare Diagnostics, IL, USA). Both techniques have been vali-
dated for use in this species (18, 21). At the conclusion of the clamp,
animals were humanely euthanized and striated muscles (mid-
gluteal muscle and left ventricle) collected. Samples were immedi-
ately frozen in liquid N and stored at−80°C until further analysis.
PROTEIN EXTRACTION ANDWESTERN IMMUNOBLOTTING
Crude membrane and total protein was extracted from frozen tis-
sue samples (50 mg) for each horse, and total protein extracted
from fresh cardiac myocytes, as previously described (22, 23).
Briefly, for crude membrane extraction, tissues were homoge-
nized (BioSpec, OK, USA) in buffer (210 mM sucrose, 40 mM
NaCl, 2 mM EGTA, 30 mM Hepes, with a protease inhibitor cock-
tail). Cells were lysed (1.2 M KCl) prior to ultra-centrifugation
at 100,000× g for 90 min at 4°C. The pellet was retained and
re-suspended in buffer (1 mM EDTA, 10 mM Tris containing
0.33%vol 16% SDS) prior to further centrifugation for 45 min
at 3,000× g. Total protein was extracted by homogenization in
Triton-X-100 extraction buffer (1% Triton-X-100, 150 mM NaCl,
50 mM of Tris-HCl, with a protease inhibitor cocktail) and cen-
trifugation for 20 min at 800× g. Protein concentration was deter-
mined for equine muscle extracts and total protein myocyte lysates
in triplicate, using the bicinchoninic acid (BCA) protein assay kit
(Pierce, IL, USA) with bovine serum albumin standards (intra-
assay CV= 1.9%). Absorbance at 562 nm was measured on a
microplate reader (Biotek, VT, USA).
Protein content of target proteins was analyzed in total
lysates [SOCS3, TLR4 (myocytes), TNF-α, and IL-6] and crude
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membrane fractions (TLR4 and GLUTs) by quantitative Western
blotting, as previously described (22, 24). Briefly, equal amounts of
protein (15–25µg) were resolved on an 8% (TLR4 and GLUTs) or
12% (IL-6, TNF-α, and SOCS3) SDS polyacrylamide gel and then
electrophoretically transferred to a polyvinylidene fluoride mem-
brane (Millipore, MA, USA) with subsequent immunoblotting.
Membranes were probed with optimally diluted primary anti-
bodies (GLUT4; 1:750, GLUT1; 1:500, GLUT8; 1:500, GLUT12;
1:500, TLR4; 1:200, IL-6; 1:500, TNF-α 1:1000, and SOCS3; 1:1000)
either at room temperature for 1 h (GLUT4) or at 4°C for 16 h
followed by incubation with an appropriate secondary antibody
(1 h at room temperature) conjugated to horseradish peroxidase.
Primary antibodies were purchased from Santa Cruz Biotechnol-
ogy (GLUT1, GLUT8, and TLR4), Abcam (GLUT12, TNF-α, and
SOCS3), R&D Systems (IL-6), and AbD Serotec (GLUT4). Protein
content was assessed by enhanced chemiluminescence reaction
(KPL, MD, USA) and quantified using a Gel-Pro Analyzer blot
scanning and analysis system (Media Cybernetics, MD, USA). The
mouse monoclonal TLR4 antibody had a close protein sequence
homology with Equus caballus (98%), and thus, was used for both
rat and equine preparations. The TNF-α and IL-6 antibodies were
equine-specific. All these antibodies have been previously vali-
dated for use in horses (25). In addition, antibodies were validated
against a positive control and equal protein loading was confirmed
by measuring calsequestrin (1:2500, Thermo Scientific) protein
expression following immunoblotting.
STATISTICAL ANALYSES
The effect of in vitro treatment on myocyte TLR4 protein content
was compared with a one-way ANOVA and Dunnett’s post hoc
test. Clinical parameters and GLUT content were compared
between p-EHC and control horse groups with a t -test. TLR4
and cytokine data did not satisfy requirements for normal dis-
tribution (Shapiro–Wilk) so were analyzed with non-parametric
analyses (Mann–Whitney). Serum insulin was correlated with
TLR4 protein content using Pearson’s correlation test. All data
were expressed as mean± standard error (SE) and significance
was accepted at p< 0.05. Statistical analyses were performed using
SigmaPlot v. 12.3.
RESULTS
EFFECT OF IN VITRO SUPRAPHYSIOLOGIC INSULIN ON CARDIAC
MYOCYTE TLR4 EXPRESSION
Isolated rat cardiac myocytes exhibited a decrease (p< 0.05) in
TLR4 protein expression by 65 and 69% when incubated with
a supraphysiological concentration of insulin (500µ IU/mL) in
the presence of both physiological (5 mM) or high (25 mM) con-
centrations of glucose, respectively, compared to basal conditions
(Figure 1A). In contrast, incubation of isolated myocytes in phys-
iological concentration of insulin (100µ IU/mL) did not result
in a change in TLR4 protein expression, compared to basal con-
ditions, in either physiological or high concentrations of glucose
(Figure 1B). Further, incubation of myocytes in both physiological
(5 mM) or high (25 mM) concentrations of glucose, in the absence
of insulin, did not significantly alter TLR4 expression compared
to basal conditions (Figure 1C).
EFFECT OF PROLONGED INSULIN INFUSION ON CARDIAC TLR4
EXPRESSION
To further investigate the role of insulin on TLR4 expression and
signaling, prolonged insulin infusion for ~46 h was performed in a
large animal model. As expected, the euglycemic hyperinsulinemic
clamp induced a marked prolonged exogenous hyperinsulinemia,
without a change in blood glucose concentration (Table 1). In
addition, prolonged hyperinsulinemia did not affect heart rate
and post-mortem examination did not reveal any gross pathologi-
cal abnormalities of the myocardium. Matched control horses did
FIGURE 1 | High concentrations of insulin decreaseTLR4 protein
expression in isolated cardiac myocytes. Top panels: representative
Western blot of TLR4 protein expression from total lysates, with calsequestrin
as a loading control. Bottom panels: mean±SE of TLR4 protein expression
(n=5/group). *p<0.05 vs. basal conditions. (A) Cardiac myocytes isolated
from healthy rats show a decrease in TLR4 protein expression after incubation
with insulin at high concentrations (HI, 500µ IU/mL) in both physiological (LG,
5 mmoL/L) and high (HG, 25 mmoL/L) concentrations of glucose, compared to
basal conditions. (B)TLR4 protein expression is not decreased in isolated
myocytes following incubation with a physiological concentration of insulin
(LI, 100µ IU/mL) in both physiological (LG, 5 mmoL/L) and high (HG,
25 mmoL/L) concentrations of glucose, compared to basal conditions.
(C) Incubation of isolated myocytes with glucose does not affect TLR4 protein
expression in the absence of insulin.
www.frontiersin.org July 2014 | Volume 5 | Article 120 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
de Laat et al. Hyperinsulinemia and cardiac TLR4
Table 1 | Mean±SE heart rate, serum insulin, and blood glucose
concentration before and after intravenous insulin infusion.
Parameter Heart rate
(beats/min)
Serum insulin
(µ IU/mL)
Blood glucose
(mmoL/L)
Control group: baseline 38±3.46 13.36±2.7 5.16±0.68
Control group: final 43±6.19 10.05±1.16 5.90±0.68
Treated group: baseline 36±3.26 22.2±11.3 5.78±0.39
Treated group: final 44±4.32 1179±228* 5.05±0.56
Heart rate did not differ between horses treated with a prolonged, euglycemic,
hyperinsulinemic clamp (p-EHC), and control horses treated with a balanced elec-
trolyte solution either before or at the conclusion of the infusion period (i.e.,
46±2.3 h). Serum insulin concentration wasmarkedly increased (*p<0.05) from
baseline levels as a consequence of treatment with a p-EHC, but not with a bal-
anced electrolyte solution (controls). However, blood glucose concentration did
not differ between groups or as a consequence of treatment.
not experience any changes in insulin or glucose concentrations
during infusion of the balanced electrolyte solution (Table 1).
Since cardiac TLR4 protein expression has not been charac-
terized in this species, we first quantified TLR4 expression across
striated muscle of healthy horses. Given that TLR4 is overwhelm-
ingly expressed on the plasma membrane and Golgi apparatus, we
specifically extracted cell membrane-rich fractions of tissue lysates
for analysis (26). We found that the myocardium expressed signifi-
cantly more TLR4 protein than the skeletal muscle (Figure 2A). In
addition, myocardial protein expression of TLR4 was decreased
(p< 0.05) by 77% in crude membrane fractions from horses
treated with a p-EHC, compared to the control group (Figure 2B).
Furthermore, there was a significant (p< 0.05) negative corre-
lation between serum insulin concentration and TLR4 protein
expression, suggesting that insulin negatively regulates TLR4 in
the myocardium (Figure 2C).
CARDIAC TLR4 SIGNALING AND GLUT EXPRESSION DURING
HYPERINSULINEMIA
To further investigate potential downstream effects of reduced
TLR4 expression in the myocardium during in vivo hyperinsuline-
mia, protein expression of the TLR4 signaling markers (SOCS3,
TNF-α, and IL-6) and GLUT (1, 4, 8, 12) was examined. Con-
comitant to the down-regulation of myocardial TLR4 protein
content, protein expression of TNF-α, IL-6, and SOCS3 did not
differ between control and p-EHC-treated animals (Figure 3).
Further, treatment with a p-EHC did not alter myocardial pro-
tein expression of basal GLUT1, insulin-sensitive GLUT4, or the
novel GLUTs (8 and 12) in membrane-enriched fractions, when
compared to controls (Figure 4).
DISCUSSION
It is well established that increased inflammation is a major patho-
genic factor in the development of many chronic diseases, includ-
ing diabetes and cardiovascular diseases (11, 27–29). Our study
demonstrated that acute and prolonged insulin exposure has a
potent suppressive effect on the expression of TLR4, a key regulator
of innate immune and inflammatory responses, in the mammalian
heart, and thus could be a promising pharmacological agent in the
treatment of cardiometabolic diseases.
Studies on TLR signaling in insulin-sensitive tissues have over-
whelmingly reported an increase in TLR4 expression during
metabolic dysfunction (13, 30). Activation of TLR4 signaling by
increased circulating FFAs during obesity-related diseases has been
suggested to be a key contributor to this up-regulation of TLR4 sig-
naling (30, 31). However, examinations of the effect of insulin on
TLR4 signaling in non-obese individuals, where circulating FFAs
are not increased, are far less common. A recent study showed
that short-term insulin infusions administered to type 1 diabetic
patients decreased TLR expression in mononuclear cells (14).
Results from the current study have also shown decreased TLR4
protein expression in a cardiac crude membrane extract during
conditions of prolonged (46 h) insulin infusion in healthy equine
subjects. In addition, acute incubation with supraphysiologic con-
centration of insulin decreased TLR4 expression in total lysate
from isolated murine cardiac myocytes. Therefore, our findings
suggested that prolonged hyperinsulinemia induces impairment
in TLR4 protein expression and/or translocation to the plasma
membrane. This premise is further supported by reports that
IGF-1, which triggers the same intracellular pathways as insulin
following receptor binding, induced suppression of TLR4 signal-
ing in skeletal muscle (32). In addition, a study demonstrating
suppression of TLR activation by phosphoinositide 3-kinase (a
key enzyme of the downstream insulin signaling pathway) indi-
cates a potential mechanism by which insulin may down-regulate
TLR signaling (33). However, further investigation of this pathway
in the non-immune cells of the heart is required. Since exces-
sive inflammation can be harmful, negative regulation of TLR4
signaling by insulin may be a protective mechanism to prevent
inappropriate innate immune responses in the heart. However,
whether hyperinsulinemia can down-regulate the activation of
TLR4 during obesity-related diseases require further investigation.
Although metabolic diseases have been overwhelmingly asso-
ciated with an inflammatory phenotype (11, 27, 29), our results
suggest that hyperinsulinemia does not directly increase pro-
inflammatory cytokine production (i.e., IL-6 and TNF-α) in the
healthy heart, suggesting that other factors, such as obesity, play a
pathogenic role during the inflammatory response. Indeed, many
of the animal models used to study cardiac inflammation and
metabolic dysfunction in vivo are complicated by obesity. Our
model of prolonged equine hyperinsulinemia is unique in that
it facilitates investigation of the effects of hyperinsulinemia in
insulin-sensitive, non-obese individuals from a species that is
prone to the development of metabolic syndrome, but not diabetes
mellitus or cardiovascular diseases (34, 35). The use of prolonged
clamping techniques in this species has added valuable informa-
tion to the field of metabolic research as the EHC is limited to
shorter periods (3–8 h) in rodents and humans (36, 37). The abil-
ity to prolong an EHC to 46 h in the horse enables the investigation
of longer term, marked hyperinsulinemia in a controlled manner.
Investigations using this model have yielded important progress
in our understanding of equine metabolic disease (38, 39). How-
ever, the impact of marked hyperinsulinemia on the healthy heart,
which was demonstrated not to be insulin-resistant at the time of
examination, by a lack of down-regulation of GLUT4 expression,
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FIGURE 2 | Prolonged hyperinsulinemia down-regulates cardiacTLR4
expression. (A,B) Representative Western blot of TLR4 protein expression
from crude membrane fractions; calsequestrin (Calsq) was used as a loading
control. (A)TLR4 protein expression is greater (p<0.05) in the heart than in
skeletal muscle in healthy horses (n=4). (B)TLR4 protein expression is
decreased (p<0.05) in horses treated with a prolonged, euglycemic,
hyperinsulinemic clamp (p-EHC), compared with control horses. (C) Serum
insulin concentration negatively correlates (Rsqr=−0.83) with myocardial
TLR4 protein content in horses treated with a p-EHC () and control
horses ().
FIGURE 3 | Markers ofTLR4 signaling are not affected by
hyperinsulinemia in horses. Top panels: representative Western blots
with calsequestrin (Calsq) as a loading control. Bottom panels: median
myocardial protein expression of the pro-inflammatory cytokines tumor
necrosis factor-alpha (TNF-α) (A) and interleukin-6 (IL-6) (B) do not differ
between horses treated with a prolonged, euglycemic,
hyperinsulinemic clamp (p-EHC), compared with control horses.
Similarly, protein content of suppressor of cytokine signaling 3 (SOCS3)
is not affected in horses treated with a p-EHC, compared with control
horses (C).
is reported here for the first time. In addition, the presence of
significantly more TLR4 in the myocardium than in skeletal mus-
cle of healthy horses in the current study would suggest that TLR
signaling is highly physiologically relevant to the heart. This is
supported by recent studies, which have provided strong evidence
that TLR4 signaling not only mediates myocardial inflammation
and ischemic injury but also contributes to cardiac dysfunction
during metabolic disease (40, 41). Studies have also shown that
defective insulin dynamics are thought to be among the earliest
pathophysiological changes in the diabetic myocardium,preceding
structural and functional changes, and thus, are of major impor-
tance in the onset and progression of cardiovascular dysfunction
during metabolic diseases (42).
The down-regulation of TLR4 combined with the lack of
increased production of pro-inflammatory cytokines (i.e., IL-6
and TNF-α) and SOCS3 following insulin infusion in the
current study suggested that hyperinsulinemia exerts an anti-
inflammatory effect on the heart in non-obese individuals. Sim-
ilarly, the anti-inflammatory effect of insulin on both immune
and non-immune cells has been demonstrated (43, 44). These
anti-inflammatory effects have also been shown to occur in vivo,
providing strong evidence that insulin has the potential to be
cardioprotective (45–47). Indeed, insulin infusion has long been
known to be effective in the treatment of patients with heart
failure or undergoing coronary bypass surgery, although its car-
dioprotective mechanisms have not been elucidated (48). It has
been suggested that the therapeutic effect of insulin could be
related to tighter glycemic control, since it has been suggested
that hyperglycemia stimulates inflammatory pathways in immune
cells (14, 49). However, in the present study, we reported that high
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FIGURE 4 | Hyperinsulinemia and concomitant down-regulation ofTLR4
does not alter glucose transporter (GLUT) protein expression. Top panels:
representative Western blots of GLUT expression from cardiac crude
membrane fractions; calsequestrin (Calsq) was used as a loading control.
Bottom panels: mean±SE protein expression of GLUTs 1 (A), 4 (B), 8 (C),
and 12 (D) do not differ in the ventricular myocardium of horses treated with a
prolonged, euglycemic, hyperinsulinemic clamp (p-EHC), compared with
control horses.
concentrations of insulin,but not of glucose,affected TLR4 expres-
sion in isolated cardiac myocytes, suggesting a new mechanism for
the cardioprotective effect of insulin. The potential for insulin to
be cardioprotective via reduced TLR4-mediated inflammation is
also highlighted by studies that demonstrated that inhibition of
TLR4 signaling preserves cardiac structure and function in non-
obese type 1 diabetic mice (41). Further, studies on adipose tissue
using mouse models with selective post-receptor, loss-of func-
tion mutations in TLR4 have demonstrated that TLR4 deficiency
is protective against the deleterious inflammatory effects associ-
ated with obesity and metabolic disease (50–53). Clearly, given
the likelihood for hyperglycemia to play a central role in cardiac
malfunction during diabetes, the impact of hyperinsulinemia on
TLR4 expression during metabolic diseases, such as in pre-diabetic
and diabetic heart disease, requires investigation (14, 54, 55).
The mechanism underlying how aberrant TLR signaling con-
tributes to cardiac IR is proposed to be related to impaired glucose
uptake into myocytes (56, 57). Glucose utilization is approxi-
mately four times greater in the myocardium than in either skeletal
muscle or adipose tissue, despite its ability to utilize other meta-
bolic substrates; thus, maintenance of normal cardiac muscle
function relies on efficient glucose uptake and utilization (42).
The heart relies principally on GLUT1 and GLUT4 (basal and
insulin-sensitive isoforms, respectively), although other novel iso-
forms, including GLUT12 and GLUT8, have recently been shown
to play important roles in cardiac function, indicating the impor-
tance of investigating all major cardiac GLUT isoforms in studies
of cardiac glucose metabolism (58, 59). However, there is consid-
erable debate on the function of these novel GLUT isoforms and
as to whether they are basal or insulin-dependent transporters,
although GLUT12 was recently characterized as a non-insulin
stimulated GLUT in the myocardium (58). This finding is in agree-
ment with the results of the current study that demonstrated that
prolonged insulin infusion did not affect the expression of basal
GLUTs in the myocardium, including GLUT1 and 12. GLUT4,
which accounts for at least 60% of the cardiac GLUTs, plays a
crucial role in whole-body glucose homeostasis (60, 61). Given
that activation of TLR4 may impair cardiac glucose metabolism, it
has been postulated that decreased TLR4 expression may improve
cardiac insulin sensitivity. The failure of membrane-rich GLUT4
expression to respond to reduced TLR4 expression secondary to
hyperinsulinemia in the current study could suggest that TLR4
signaling does not primarily regulate glucose transport in the
myocardium in contrast to the skeletal muscle (62). Indeed, the
regulation of glucose transport has been shown to be tissue spe-
cific. Since the heart contracts constantly, it has been suggested
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that calcium/contraction pathways are also major regulators of
GLUT4 translocation in the myocardium (63). Therefore, the reg-
ulation of cardiac glucose metabolism by insulin-independent
pathway and the relative function of cardiac GLUTs requires fur-
ther investigation. In addition, glucose transport could have also
been regulated by other factors (e.g., transcriptional) that may not
have been detected by the end time point of the prolonged clamp
(i.e., 46 h). Therefore, the relationship between TLR4 signaling
and GLUT regulation in the heart is intriguing and further inves-
tigation may not only uncover new mechanisms for cardiac IR but
also allow identification of novel therapeutic targets for diabetic
cardiomyopathy.
Overall, the current study has presented the novel finding that
negative regulation of TLR4 expression exists in the heart dur-
ing hyperinsulinemia using an integrative approach, including a
unique, large animal model. This study shows the potential for
insulin to be cardioprotective via reduced TLR4-mediated inflam-
mation and this finding requires further investigation in human
diabetic patients. Inactivation of aberrant TLR4 function during
metabolic disease may provide novel therapeutic targets for the
treatment or prevention of cardiovascular diseases in individuals
with diabetes.
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